Key facts & figures
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Sanofi-aventis is a global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business is diversified and includes pharmaceuticals comprising Rx (prescription) drugs, OTC/OTX (over-the-counter / combined OTC and Rx drugs) and generics; vaccines and animal health.
- 2008 net sales: €27,568 million, +3.1%* versus 2007
- 2008 adjusted EPS excluding selected items**: €5.49, +6.2% versus 2007 or +11.2% at constant €/$ exchange rate
- H1 2009 net sales: €14,545m, +3.1% at constant exchange rates versus H1 2008
- H1 2009 adjusted EPS excluding selected items**: €3.41, +13.4% at constant exchange rates versus H1 2008
Pharmaceuticals business
Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: thrombosis, cardiovascular diseases, diabetes, oncology, central nervous system (CNS) and internal medicine.
- 2008 net sales of the pharmaceuticals business: €24,707 million, +3.1%* versus 2007
- H1 2009 net sales of the pharmaceuticals business: €13,206 million, +3.0% at constant exchange rates versus H1 2008
The Rx drugs(1) activity counts 5 leading brands with double-digit growth in 2008.
- 2008 net sales of Rx drugs: €22,943 million, +2.9%* versus 2007
- Market share: 4.8%
- Rank: #4
- H1 2009 net sales of Rx drugs: €12,189 million
Pharmaceuticals business| €million | Therapeutic area | 2008 sales | % change*
(vs. 2007) |
|---|
| Lovenox® | Thrombosis | 2,738 | +10.6% |
|---|
| Plavix® | Thrombosis | 2,616 | +10.5% |
|---|
| Lantus® | Diabetes | 2,450 | +27.7% |
|---|
| Taxotere® | Oncology | 2,033 | +13.2% |
|---|
| Aprovel® | Cardiovascular | 1,202 | +14.2% |
|---|
Note: Worldwide presence* of Plavix® is €6,143 million, +15.3%. Worldwide presence* of Aprovel® is €1,966 million, +10.8%.
Sanofi-aventis also has a significant presence in OTC/OTX(2), in various product categories.
- 2008 net sales of OTC/OTX: €1,415 million, +5.3%* versus 2007
- Market share: 2.1%
- Rank: #6
- H1 2009 net sales of OTC/OTX: €640 million, +16.2% at constant exchange rates versus H1 2008
In addition to Rx drugs and OTC/OTX, the pharmaceuticals business comprises generics(1).
- 2008 net sales of generics: €349 million, +8.7%* versus 2007
- Market share: <1%
- Rank: #23
With the acquisition of the Czech generics company Zentiva, Kendrick in Mexico and Medley in Brazil sanofi-aventis ranks 8th worldwide, based on pro forma 2008 sales of €1.2 billion (IMS / Cegedim 2008 pro forma data).
- H1 2009 net sales of generics: €377 million, +129.7% at constant exchange rates versus H1 2008
(1) Market share and ranking from internal analysis based on IMS MIDAS MAT Q3 2008
(2) Market share and ranking from Nicholas Hall, 2007.
Vaccines business
Sanofi Pasteur, the fully integrated vaccines business(1) of sanofi-aventis, is the world leader in the vaccines industry offering the broadest range of vaccines in five areas: influenza, pediatric combinations and poliomyelitis vaccines, adult and adolescent booster vaccines, meningitis as well as travel, endemic and measles, mumps, rubella (MMR) vaccines.
- 2008 net sales of the vaccines business: €2,861 million, +9.6%* versus 2007
- Non-consolidated 2008 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €1,272 million, +21.8%
- Market share: 21.8%
- Rank: #1
- H1 2009 net sales of the vaccines business: €1,339 million, +3.7% at constant exchange rates versus H1 2008
- Non-consolidated H1 2009 sales of Sanofi Pasteur MSD: €487 million, -11.8% on a reported basis
2008 net sales of the vaccines business| € million | 2008 sales | % change*
(vs. 2007) |
|---|
| Polio/Whooping Cough/Hib Vaccines | 768 | +21.9% |
|---|
| Influenza vaccines | 736 | +1.5% |
|---|
| Meningitis/pneumonia vaccines | 472 | +7.0% |
|---|
| Adult booster vaccine | 399 | +8.1% |
|---|
| Travel vaccines | 309 | -1.6% |
|---|
| Other vaccines | 177 | +34.1% |
|---|
| TOTAL | 2,861 | +9.6% |
|---|
(1) Market share and rank based on sanofi pasteur internal estimates at end Dec. 2008 and on worldwide presence including 50% of Sanofi Pasteur MSD joint-venture sales.
Animal health
Merial, a subsidiary of sanofi-aventis, is one of the world’s leading animal health(1) companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.
- Non-consolidated 2008 sales of Merial: $2,643 million, +7.9% versus 2007
- Market share: 13.8%
- Rank: #3
(1) Market share and ranking based on 2008 public data
Geographic presence
Sanofi-aventis has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. Our presence is well-balanced between traditional (Europe, North America and Japan) and emerging markets. Sanofi-aventis is the established leader in emerging markets, holding top positions in the main countries.
2008 Geographic presence| € million | 2008 sales | % change*
(vs. 2007) |
|---|
| Europe | 12,096 | -0.6% |
|---|
| United States | 8,609 | +5.4% |
|---|
| Other countries | 6,863 | +10.1% |
|---|
* Change on a “comparable” basis.
** See our Glossary for the definition of financial indicators
